Day: February 7, 2020

Utbyttebeløp: NOK 1.25Annonsert valuta: NOKSiste dag inklusive: 11 May 2020Ex-dato: 12 May 2020Record date: 13 May 2020Betalingsdato: 20 May 2020Vedtaksdato: 11 May 2020Investor kontaktStian HasleTlf +47 97736022E-mail stian.hasle@hydro.comDenne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12

Hydro’s underlying earnings before financial items and tax was NOK 560 million in the fourth quarter, a slight increase from NOK 534 million in the same quarter last year. This mainly reflected positive effects from increased production in Brazil, lower raw material costs and positive currency effects, mostly offset by a decrease in the realized aluminium and alumina prices.Underlying EBIT of NOK 560 millionChallenging markets weighing on resultsBNOK 1 in improvement program delivered in 2019, above target of BNOK 0.5Cash release ahead of target in 2019Increasing sales of low-carbon productsProposed dividend for 2019 of NOK 1.25 per share“We have taken firm measures in a weak market. Our improvement program as well as cash release ambition are ahead of plan. Our improvement efforts will continue with full force, in line with...

Hydros underliggende resultat før finansposter og skatt var 560 millioner kroner i fjerde kvartal, en liten økning sammenliknet med 534 millioner kroner i samme kvartal i fjor. Dette reflekterer hovedsakelig positive effekter av økt produksjon i Brasil, en nedgang i råvarekostnader og positive valutaeffekter, som for det meste ble utliknet av en nedgang i realiserte priser på aluminium og alumina.Underliggende EBIT på 560 millioner kronerUtfordrende markeder påvirker resultatene1 milliard kroner oppnådd gjennom forbedringsprogrammet i 2019, over målsetting på 0,5 milliarder kroner.Frigjøring av midler foran målsetting for 2019Økende salg av lavkarbonprodukterForslag til utbytte på 1,25 kroner per aksje– Vi har iverksatt kraftige tiltak...

The January–December 2019 revenue improved slightly compared to previous year and operating result remained unchanged.October–December 2019Revenue was EUR 29.9 million (27.8), representing a change of 7.3 %The result for the period was EUR 0.6 million (-0.2)Operating profit per revenue was 1.9 % (-0.8 %)The result for the period improved and was EUR 0.5 million (-0.1)Earnings per share amounted to EUR 0.11 (-0.02)January–December 2019Revenue was EUR 106.2 million (103.1), representing a change of 3.0 %Comparable operating result was EUR -1.6 million (-2.1)Operating result according to IFRS was EUR -2.0 million (-2.1)Operating profit per revenue was -1.9 % (-2.0 %)The result for the period was EUR -2.5 million (-2.4)Earnings per share amounted to EUR -0.61 (-0.57)OutlookOutlook for 2020The Martela Group anticipates that...

Tammi-joulukuun 2019 liikevaihto parani hieman edellisen vuoden vastaavaan ajankohtaan verrattuna ja liiketulos pysyi samalla tasolla.Loka-joulukuu 2019Liikevaihto oli 29,9 MEUR (27,8), muutos 7,3 % Liiketulos oli 0,6 MEUR (-0,2)Liikevoittoprosentti oli 1,9 % (-0,8 %)Tilikauden tulos parani ja oli 0,5 MEUR (-0,1)Osakekohtainen tulos oli 0,11 euroa (-0,02)Tammi-joulukuu 2019Liikevaihto oli 106,2 MEUR (103,1), muutos 3,0 % Vertailukelpoinen liiketulos oli -1,6 MEUR (-2,1)IFRS mukainen liiketulos oli -2,0 MEUR (-2,1)Liikevoittoprosentti oli -1,9 % (-2,0 %)Tilikauden tulos oli -2,5 MEUR (-2,4)Osakekohtainen tulos oli -0,61 euroa (-0,57)NäkymätNäkymät vuodelle 2020 Martela-konsernin koko vuoden 2020 liikevaihdon ja liiketuloksen arvioidaan paranevan hieman edellisvuotisesta. Perinteisesti konsernin liiketulos...

Notice is given to the shareholders of Martela Corporation to the Annual General Meeting to be held on 12 March 2020 at 3 pm at Martela -house, address Takkatie 1, 00370 Helsinki.The reception of persons who have registered for the meeting and the distribution of voting tickets will commence at 2.30 pm.A. Matters on the agenda of the Annual General MeetingAt the Annual General Meeting, the following matters will be considered:1. Opening of the meeting2. Calling the meeting to order3. Election of persons to scrutinize the minutes and to supervise the counting of votes4. Recording the legality of the meeting5. Recording the attendance at the meeting and adoption of the list of votes6. Presentation of the annual accounts, the report of the Board of Directors andthe auditor’s report for the year 2019– Review by the CEO.7. Adoption...

Martela Oyj:n osakkeenomistajat kutsutaan varsinaiseen yhtiökokoukseen, joka pidetään torstaina 12.3.2020 klo 15.00 Martelatalossa, Takkatie 1, 00370 Helsinki.Kokoukseen ilmoittautuneiden vastaanottaminen ja äänestyslippujen jakaminenaloitetaan klo 14.30.A. Yhtiökokouksessa käsiteltävät asiatYhtiökokouksessa käsitellään seuraavat asiat:1. Kokouksen avaaminen2. Kokouksen järjestäytyminen3. Pöytäkirjantarkastajien ja ääntenlaskun valvojien valitseminen4. Kokouksen laillisuuden toteaminen5. Läsnä olevien toteaminen ja ääniluettelon vahvistaminen6. Vuoden 2019 tilinpäätöksen, toimintakertomuksen ja tilintarkastuskertomuksen esittäminen– Toimitusjohtajan katsauksen esittäminen.7. Tilinpäätöksen...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATESVANCOUVER, British Columbia, Feb. 06, 2020 (GLOBE NEWSWIRE) — Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has closed the first tranche of its $3,000,000 prospectus offering (the “Offering”) announced in its news release dated January 6, 2020.Pursuant to this initial closing, Emerald has issued an aggregate of 7,596,551 units of Emerald (each, a “Unit”) at a price of $0.29 per unit for total gross proceeds of $2,203,000. Emerald will issue the remaining 2,748,276 Units, for gross proceeds of $797,000, upon receipt of all necessary approvals, including the approval of the TSX Venture Exchange and applicable securities regulatory authorities.Each Unit consists of one common share of...

TOKYO, Feb. 07, 2020 (GLOBE NEWSWIRE) — Internet Initiative Japan Inc. (“IIJ”, TSE: 3774) today announced its nine months consolidated financial results for the fiscal year ending March 31, 2020 (“1Q-3Q19”, from April 1, 2019 to December 31, 2019) under International Financial Reporting Standards (IFRS).1Overview of 1Q-3Q19 Financial Results and Business Outlook“We continued to achieve stronger than expected enterprise revenue and profit growth, supported by overall favorable Japanese enterprises’ IT demands and our growth strategy of cross-selling various network services, combined with systems integration. In this nine-month period, enterprise recurring revenues6 grew by 10.0% YoY in which enterprise mobile, security, and cloud especially strongly grew by 25.1%, 17.4% and 16.2% respectively....

DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 06, 2020 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), announced today that BioNJ awarded Amarin with an Innovator Award in recognition of the approval of a new indication for VASCEPA® (icosapent ethyl) by the U.S. Food and Drug Administration (FDA) in December 2019. This approval positions VASCEPA as the first and only drug approved to reduce cardiovascular events in millions of select high-risk patients. The approval follows over a decade of research and development in a clinically challenging disease area characterized by significant unmet medical need.“Amarin is proud to be part of BioNJ’s business community,” stated Steven Ketchum, PhD, Amarin’s president of R&D and chief scientific officer, who accepted the award on Amarin’s behalf....